On June 25, 2025, the FDA approved revumenib for acute leukemia, and data was presented at the EHA Congress in Milan.
1 report, 0 independent
Updated Jun 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
On June 25, 2025, the FDA approved revumenib for acute leukemia, and data was presented at the EHA Congress in Milan.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- AstraZeneca presented data at the EHA 2025 Congress in Milan.Sub-event
- FDA approved revumenib, and EHA Congress data was presented in Milan.
Keep exploring
The entities involved
- FDA
-
Syndax Pharmaceuticals
business
Nothing else this week.
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- SharpLink Gaming acquired Ethereum above market prices, causing a stock price drop, while Trump tariffs continue to benefit AI stocks.
- Atai Life Sciences, a German-headquartered company, is seeking FDA meetings and study results while benefiting from Trump-era tariffs.
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
Coverage
Newest first; wire copies grouped- Unknown outlet